Here's what you should know about antibiotics in these situations:
- Ear infections ...
FOR IMMEDIATE RELEASE
Contacts: Clay Holtzman, Swedish, 206-386-2748, firstname.lastname@example.org
Swedish Honored at Leaders in Health Care 2014 Event
Seattle Business magazine recognizes Swedish for Outstanding Community Outreach
SEATTLE — Feb. 25, 2014 — Swedish Health Services’ Community Benefits Program received the Outstanding Community Outreach award at Seattle Business magazine’s fifth annual Leaders in Health Care awards celebration. The largest and most comprehensive non-profit health provider in the Pacific Northwest, Swedish is known for creating high-impact community outreach programs such as the Swedish Community Specialty Clinic and Global to Local (G2L).
The Leaders in Health Care awards honor 25 outstanding organizations in eight categories, ranging from medical research to lifetime achievement. The Outstanding Community Outreach award recognizes organizations that are committed to developing and implementing original programs that improve the health of local communities.
“It is an honor to be recognized with such a prestigious award,” said Tom Gibbon, manager of the Swedish Community Specialty Clinic and Ballard High School Teen Clinic. “It showcases years of work that not only benefits the most vulnerable populations in our community, but also offers sustainable and replicable solutions that will change how care is delivered.”
The Swedish Community Benefits Program evaluates public health data and collaborates with local organizations to produce initiatives that address a wide range of community health needs in the Pacific Northwest. Since 2006, Swedish has launched more than 15 initiatives. Programs such as the Swedish Community Specialty Clinic and Global to Local exist to combat long-term challenges while addressing immediate health care needs.
Recent news about the health of the distinguished journalist, Tom Brokaw, has focused attention on multiple myeloma, a malignant disease of the bone marrow. Myeloma is characterized by an uncontrolled growth of marrow plasma cells, which normally produce antibodies for our immune system. In its advanced stages, the overgrowth of these cells and their associated proteins can cause anemia, painful bone destruction, and kidney failure.
Until about 10 years ago, advanced myeloma was uniformly fatal with a typical survival of about 3 years. Recent years, however, have seen a remarkable improvement in treatment possibilities for myeloma. This began with the discovery that autologous stem cell transplantation could produce complete remissions and longer survival. In addition, a variety of chemotherapy drugs administered in combination with corticosteroid drugs, now produce responses in up to 80% of patients. This means about 80% of patients are surviving longer than 3 years after chemotherapy and autologous stem cell transplant.
Not all patients with myeloma require chemotherapy. Myeloma can exist in an early stage for years. This is called smoldering myeloma. Chromosome analysis is routinely done on myeloma cells and allows us to identify patients with more aggressive forms of the disease, and those requiring treatment due to signs of organ damage or bone pain.
The Swedish Cancer Institute has been a participant in clinical trials leading to the development of some of the effective new treatments for myeloma. We are currently participating in a study of pomalidomide, a newly approved agent, for patients with relapsed myeloma. Another study offers an investigational drug, MLN9708, for newly diagnosed patients.
While the new drugs are more effective and better tolerated than previous chemotherapy, all ...